QURE INVESTIGATION: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

Core Viewpoint - The law firm Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of investors in uniQure N.V. following significant stock price decline after FDA feedback on its gene therapy AMT-130 [1][2][3] Group 1: Company Developments - On November 3, 2025, uniQure announced that the FDA indicated the data for its investigational gene therapy AMT-130 for Huntington's disease was insufficient to support its Biologics License Application (BLA) [2] - uniQure believes the FDA no longer considers the Phase I/II study data adequate for BLA submission, leading to uncertainty regarding the timing of the BLA submission for AMT-130 [2] Group 2: Market Reaction - Following the FDA's announcement, uniQure's stock price plummeted over 50%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [3]